Amid the reality of ever shrinking pipelines, strong project management has become a mainstay of good PPM decision making. Gain strategic, as well operational, insights into the latest trends and practices from top-tier industry experts at the 4th annual Pharma PPM Toolbox.

Building on their expertise, EBCG strives to provide you with the best possible platform for sharing PPM topics exclusively focused on the pharmaceutical industry. Our track record in developing such platforms speaks for itself. Consider what attendees of the most recent Pharma PPM Toolbox series had to say on the matter:

One of the best conferences I have ever attended very interesting and stimulating presentations, and -discussions, and excellent networking opportunities as well.

Head of R&D Project Management Late Stage at Boehringer Ingelheim

I enjoyed the meeting pretty much. It provided me a good insight into other companies project management organizations and gave me some new ideas to improve our work.

R&D Project Leaderat Boehringer Ingelheim

Congratulations on bringing together such a large group of professionals. You have managed to balance topics related to project management & planning vs. portfolio management very well.

Head of Portfolio Management& Reporting at Sanofi Aventis

A very good program covering a wide variety of topics all of which were relevant.

Director, Biopharm Managementat Novo Nordisk

Tel.: +421 2 3220 2200 Fax: +421 2 3220 2222

ppm@ebcg.bizwww.ebcg.biz

4 Ways to contact us:

* 10 Professional Development Units B category can be claimed with the Project Management Institute(supported by a certificate of attendance issued by EBCG)

Who can you expect to meet?Project Portfolio Directors, R&D Directors, Program Directors,Project Leaders, Senior Project Team Members, Brand DirectorsLine Function Managers in: Project and Portfolio Management,Global R&D, Strategic Planning, Global Program, Portfolio Planning,Development Finance and Strategic SourcingFrom EMEA region

NetworkingopportunitiesEvening Cocktail ReceptionFavourite Coffee SpotFocused Panel Discussions & Breakout Sessions

Silver Sponsors:

Gold Sponsor:

http://ebcg.biz/ebcg-business-events/53/2014-pharma-ppm-toolbox/http://ebcg.biz/ebcg-business-events/53/2014-pharma-ppm-toolbox/

Nu

mb

er o

f Del

egat

es

2014 - prediction

2011 2012 2013 2014

60+

80+

100+

Annual Growth

Watch our video from2013 Pharma PPM Toolbox!

130+

Or feel free to ask on possible combinations and enhance your participation by choosing one day from the collocated training.The two day training is designed to give attendees of the Toolbox conference an additional full-day of professional development:

Peter WittnerSenior Consultant INTERPHARMConsultancy

Biosimilars Understanding the Regulatory Processes and the Commercial Realities

19th March 2014 - Workshop

Anthony ElleryPresident, Former Global HeadLCM in Portfolio Managementat Novartis Ellery Pharma Consulting

Lifecycle Management

19th & 20th March 2014 - Collocated Training

n Regulatory, legal, scientific, medical, technical and commercial options for optimizing the brand life cycle, from early development through to the post-patent afterlifen What are the sustainable options in an ever-tightening cost-containing environment?n Options for a compelling, brand-specific, integrated LCM Plan

click here for more information

Biosimilars, biogenerics, follow-on biologicals and their potentialn What are we actually talking about?n Summary of issues affecting Biosimilars (regulatory, legal/IP, commercial)n Interchangeability what is the issue?

The regulatory process and its pitfallsn Europe a straight forward case (EMEA guidelines, successful and failed applications)n USA how will the new legislation work out?n Japan compared to EU or USn Situation in other markets

Biosimilars the commercial realityn What is the big attraction? Biologicals market and prospects; potential Biosimilars marketn What has happened so far?n Patents, IP and other issues (differing national legislation)n Where do Biosimilars go from here?

REGIsTRATION & COFFEE

WELCOME & INTRODUCTION

13.30

14.00

COFFEE & NETWORKING15.45

END OF WORKsHOP17.45

JOINED NETWORKING COCKTAIL RECEPTION18.00

14.10

14.45

16.15 Attendees of the Biosimilars Workshop and Lifecycle Management Training arecordially invited to a networking reception. Follow up on discussions started during the day, and enjoy fine snacks with the delicious drinks!

SIMPly, havEa GooD tIME!

http://events.ebcg.biz/pharma-lcm/%3Futm_source%3Dagenda%26utm_medium%3Dbanner%26utm_campaign%3Dppmagenda

Hartmut HeinDirector, Head of GlobalPlanning OfficeMerck Serono

Paolo MazzoniCEOPTM Consulting

Christine DeuschelVP Portfolio and Project ManagementDebiopharm

Gerrit BuurmanPrincipalCatenion

Hans-JurgenFederselSenior Principal Scientist,PhD, Assoc ProfessorAstra Zeneca

ReGiSTRATion & CoFFee8.30

oPeninG ReMARkS FRoM THe CHAiR9.00

SPeeD neTwoRkinG 9.10

STRATEGIC PHARMA PPM9.20

MoRninG CoFFee & neTwoRkinG10.30

LunCHeon FoLLoweD By CoFFee AnD neTwoRkinG13.00

CASe STuDy: PPM Introduction to the Project Evaluation11.00

n From the Start-up to the Big Pharma companies. How to measure the complexity with the same criteria (and have success) n Step by step methodology using Stage and Gate approachn Objective evaluation for strategic decision: Introducing MRL model n Data manipulation in a scientific environment. Bayesian Statistic and Expert Elicitation Modeln Q&A

PReSenTATion: Portfolio Drivers: Bringing all the Elements Together11.40

n Portfolio decisions based on sound datan The review process and follow up n Portfolio performance tips, or how to avoid late-stage attritionn Q&A

9.50 PReSenTATion: How to Implement Integrated R&D Operation

keynoTe PReSenTATion: Facing Strong Headwinds Pharma Under Pressureto Define a Sustainable Future

n The historical legacy leading up to industrys current experience of harsh realitiesn What countermeasures can be taken to prevent further decline?n Is a prosperous future possible and will industry achieve sustainability?n Q&A

n Convincing senior management n Evaluation of the right partner n Start implementation of integrated Planning and Business Operationsn Q&A

PReSenTATion: Portfolio Management for Early Stage Assets 12.20

n Context for R&D Decision Making, n Project Level Decision Making for Early Stage Assets,n Portfolio Level Decision Makingn Q&A

We cordially invite you to a networking reception. Meet your peers,continue in discussions, and enjoy fine snacks with the delicious drinks.

CLoSinG ReMARkS FRoM THe CHAiR18.10

AFTeRnoon CoFFee & neTwoRkinG15.50

neTwoRkinG CoCkTAiL ReCePTion 18.30

14.30 CASe STuDy: Navigating through the Regulatory Changes in Europen Increase your portfolio value for patients by benefiting from the new process of Parallel Scientific Advice with CHMP and Health Technology Assessment bodiesn Q&A

17.00 PReSenTATion: Resourcing Pharma Projects for Improved Outcomesn TBA n Q&A

17.40 PAneL DiSCuSSion: Changing the Blueprint of Pharman Balancing scientific and commercial risk in the pursuit of relevancen Innovative internal structures, M&A, collaborations with VCs, academic institutions, government grantsn New sources of innovation, and the challenges they bear for the R&D and commercial teamsn Macro or micro? Should the pharma industry be looking more at personalised medicine rather than concentrating on one-size-fits-all blockbusters?n Q&A

15.10 PReSenTATion: Late Stage Brands Should you Invest?n When brands go off-patentn When is the time to stop investingn Q&A

TRENDS AND FORECASTS

SIMPLy, HAvE A gOOD TIME!

emmanuel FaureDirector GlobalRegulatory Affairsnovartis

Holger MllerSVP CommercialOperationsCell Medica

Pasi PiitulainenSenior Director, Clinical Development Finance and Strategic SourcingActelion

Mary ellen yarossiRegional Director EMEAindependent Project Analysis

CASe STuDy: The Benefits and Shortfalls of Outsourcing16.20

n Why are companies outsourcingn Outsourcing as a strategic tooln Mini Case: Defining the outsourcing strategyn Q&A

Christine DeuschelVP Portfolio and Project ManagementDebiopharm

Peter wittnerSenior ConsultantinTeRPHARMConsultancy

Hans-Jurgen FederselSenior Principal Scientist,PhD, Assoc ProfessorAstra Zeneca

(TBA)

11.20 CASe STuDy: Spotting Project Errorsn Avoiding project failuresn Seeing the warning signs early onn The swan song: terminating the projectn Q&A

CASe STuDy: Holistic Portfolio Review at Bayer

n Quantitative and qualitative assessmentn Review process, project team input and management alignmentn Strategic and operational prioritiesn Q&A

12.00 CASe STuDy: Project Leadership Competencies:Separating Fact from Fiction

n Project leadership competencies: fictions!n Data gathered from EU and USA based research on project leadershipn Project leadership competencies: facts!n Implications for the development of highly capable project leadership in the life science industriesn Building the needed competencies: no gain without painn Q&A

12.00

Track A Morning Track B Morning